




Instance: composition-en-1cafc851e1f0aed5863b6a73ba46d0f7
InstanceOf: CompositionUvEpi
Title: "Composition for nubeqa Package Leaflet"
Description:  "Composition for nubeqa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1cafc851e1f0aed5863b6a73ba46d0f7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nubeqa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What NUBEQA is and what it is used for </li>
<li>What you need to know before you take NUBEQA </li>
<li>How to take NUBEQA </li>
<li>Possible side effects </li>
<li>How to store NUBEQA </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What nubeqa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nubeqa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>NUBEQA contains the active substance darolutamide.<br />
It is used to treat adult men with prostate cancer that:</p>
<ul>
<li>has not spread to other parts of the body and no longer responds to medical or surgical treatment 
that lowers testosterone (also called non-metastatic castration-resistant prostate cancer) </li>
<li>has spread to other parts of the body and responds to medical or surgical treatment that lowers 
testosterone (also called metastatic hormone-sensitive prostate cancer). </li>
</ul>
<p>How NUBEQA works 
NUBEQA blocks the activity of male sex hormones called androgens, such as testosterone. By blocking 
these hormones, darolutamide stops prostate cancer cells from growing and dividing. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nubeqa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nubeqa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take NUBEQA if 
- you are allergic to darolutamide or any of the other ingredients of this medicine (listed in 
section 6) 
- you are a woman who is or may become pregnant. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking NUBEQA if 
- you have problems with your kidneys 
- you have problems with your liver 
- you have any heart conditions including heart rhythm problems or if you are using medicines 
for these conditions 
- you had a surgery to treat blood vessel conditions. </p>
<p>Taking this medicine may affect your liver tests. If your blood tests show abnormal results of your 
liver function, your doctor may decide to stop treatment permanently. </p>
<p>Children and adolescents 
This medicine is not for use in children and adolescents under 18 years. Prostate cancer does not occur 
in this age group. </p>
<p>Other medicines and NUBEQA 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>The following medicines may influence the effect of NUBEQA, or NUBEQA may influence the effect 
of these medicines to treat:</p>
<ul>
<li>bacterial infections, such as rifampicin </li>
<li>epilepsy, such as carbamazepine, phenobarbital, phenytoin </li>
<li>symptoms of slightly low mood and mild anxiety: St. John's wort (a herbal medicine) </li>
<li>high cholesterol, such as rosuvastatin, fluvastatin, atorvastatin, pitavastatin </li>
<li>severe joint inflammation, severe cases of the skin disease psoriasis, and cancers: methotrexate </li>
<li>inflammatory bowel diseases: sulfasalazine </li>
</ul>
<p>Your doctor may therefore change the dose of the medicines that you are taking. </p>
<p>Pregnancy, breast-feeding and fertility 
NUBEQA is not for use in women. 
This medicine could possibly have an effect on male fertility. 
Follow these advices during and for 1 week after stopping:</p>
<ul>
<li>use a highly effective method of contraception to prevent pregnancy, if you are having sex with 
a woman who can become pregnant. </li>
<li>use a condom to protect the unborn baby, if you are having sex with a pregnant woman. </li>
</ul>
<p>Driving and using machines 
This medicine is unlikely to affect your ability to drive and use machines. </p>
<p>NUBEQA contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nubeqa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nubeqa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.  </p>
<p>The recommended dose is 
2 tablets 2 times daily </p>
<p>Your doctor may reduce your dose to 1 tablet 2 times daily, if you have problems with your liver or 
kidneys. 
Method of use 
Swallow the tablets whole, take them with food and a glass of water. </p>
<p>Your doctor may also prescribe other medicines while you are taking NUBEQA. </p>
<p>If you take more NUBEQA than you should 
Continue the treatment with the next dose as scheduled. </p>
<p>If you forget to take NUBEQA 
Take your missed dose as soon as you remember before the next scheduled dose. Do not take a double 
dose to make up for 1 or more forgotten tablets. </p>
<p>If you stop taking NUBEQA 
Do not stop taking this medicine unless your doctor tells you to. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Side effects of NUBEQA occur with the following frequencies: </p>
<p>In patients with non-metastatic castration-resistant prostate cancer 
Very common side effects (may affect more than 1 in 10 people):</p>
<ul>
<li>tiredness </li>
<li>blood tests showing reduced number of a white blood cell type called neutrophils </li>
<li>blood tests showing increased levels of substances produced by the liver: bilirubin, aspartate 
transaminase </li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people):</p>
<ul>
<li>blockage of the arteries in the heart </li>
<li>heart failure </li>
<li>rash </li>
<li>pain in arms and legs </li>
<li>pain in muscles and bones </li>
<li>broken bones </li>
</ul>
<p>In patients with metastatic hormone-sensitive prostate cancer 
Very common side effects (may affect more than 1 in 10 people):</p>
<ul>
<li>high blood pressure </li>
<li>rash </li>
<li>blood tests showing reduced number of a white blood cell type called neutrophils </li>
<li>blood tests showing increased levels of substances produced by the liver: bilirubin, alanine 
transaminase and aspartate transaminase </li>
</ul>
<p>Common side effects (may affect up to 1 in 10 people):</p>
<ul>
<li>broken bones </li>
<li>breast enlargement in men </li>
</ul>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nubeqa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nubeqa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on each blister after 
EXP. The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What NUBEQA contains 
The active substance is darolutamide. Each film-coated tablet contains 300 mg of darolutamide. 
The other ingredients are:</p>
<ul>
<li>calcium hydrogen phosphate (E 341) </li>
<li>croscarmellose sodium </li>
<li>hypromellose </li>
<li>lactose monohydrate </li>
<li>macrogol (E 1521) </li>
<li>magnesium stearate (E 470b) </li>
<li>povidone (E 1201) </li>
<li>titanium dioxide (E 171) </li>
</ul>
<p>See  NUBEQA contains lactose  in section 2 for more information. </p>
<p>What NUBEQA looks like and contents of the pack 
The film-coated tablets (tablets) are white to off-white, oval with a length of 16 mm and a width of 
8 mm. They are marked with  300  on one side, and  BAYER  on the other side. </p>
<p>Each carton contains:</p>
<ul>
<li>96 film-coated tablets consisting of 6 blisters or </li>
<li>112 film-coated tablets consisting of 7 blisters </li>
</ul>
<p>Each blister contains 16 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Bayer AG 
51368 Leverkusen 
Germany </p>
<p>Manufacturer 
Orion Corporation, Orion Pharma 
24100 Salo 
Finland 
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Bayer SA-NV 
T l/Tel: +32-(0)2-5356Lietuva 
UAB Bayer 
Tel. +37 05 23 36   </p>
<p>T .: +359 (0)2 424 72 Luxembourg/Luxemburg 
Bayer SA-NV 
T l/Tel: +32-(0)2-535 63  esk  republika 
Bayer s.r.o. 
Tel: +420 266 101 Magyarorsz g 
Bayer Hung ria KFT 
Tel:+36 14 87-41 Danmark 
Bayer A/S 
Tlf: +45 45 23 50 Malta 
Alfred Gera and Sons Ltd. 
Tel: +35 621 44 62 Deutschland 
Bayer Vital GmbH 
Tel: +49 (0)214-30 513 Nederland 
Bayer B.V. 
Tel: +31-23-799 1Eesti 
Bayer O<br />
Tel: +372 655 8Norge 
Bayer AS 
Tlf: +47 24 11 18 <br />
Bayer   <br />
 : +30 210-618 75  sterreich 
Bayer Austria Ges.m.b.H. 
Tel: +43-(0)1-711 46-0 
Espa a 
Bayer Hispania S.L. 
Tel: +34-93-495 65 Polska 
Bayer Sp. z.o.o. 
Tel: +48 22 572 35 France 
Bayer HealthCare 
T l (N  vert): +33-(0)800 87 54 Portugal 
Bayer Portugal, Lda. 
Tel: +351 21 416 42 Hrvatska 
Bayer d.o.o. 
Tel: +385-(0)1-6599 Rom nia 
SC Bayer s.r.l. 
Tel: +40 21 529 59 Ireland 
Bayer Limited 
Tel: +353 1 216 3Slovenija 
Bayer d. o. o. 
Tel: +386 1 58 14  sland 
Icepharma hf. 
S mi: +354 540 8Slovensk  republika 
Bayer spol. s r.o. 
Tel. +421 2 59 21 31 Italia 
Bayer S.p.A. 
Tel: +39 02 397 Suomi/Finland 
Bayer Oy 
Puh/Tel: +358 20 785 <br />
NOVAGEM Limited 
T : +357 22 48 38 Sverige 
Bayer AB 
Tel: +46 (0) 8 580 223 Latvija 
SIA Bayer 
Tel: +371 67 84 55 United Kingdom (Northern Ireland) 
Bayer AG 
Tel: +44-(0)118 206 3This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-1cafc851e1f0aed5863b6a73ba46d0f7
InstanceOf: CompositionUvEpi
Title: "Composition for nubeqa Package Leaflet"
Description:  "Composition for nubeqa Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1cafc851e1f0aed5863b6a73ba46d0f7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nubeqa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage NUBEQA
3. Sådan skal du tage NUBEQA
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What nubeqa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nubeqa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>NUBEQA indeholder det aktive stof darolutamid.
Det anvendes til at behandle voksne mænd med prostatakræft, som:
-
ikke har spredt sig til andre dele af kroppen, og som ikke længere reagerer på medicinsk eller 
kirurgisk behandling, der sænker testosteron (også kaldet ikke-metastatisk kastrationsresistent 
prostatakræft)
-
har spredt sig til andre dele af kroppen og reagerer på medicinsk eller kirurgisk behandling, der 
sænker testosteron (også kaldet metastatisk hormonfølsom prostatakræft).
Sådan virker NUBEQA
NUBEQA blokerer aktiviteten af mandlige kønshormoner, der kaldes for androgener, såsom 
testosteron. Ved at blokere disse hormoner, forhindrer darolutamid prostatakræftcellerne i at vokse og 
dele sig.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nubeqa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nubeqa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Tag ikke NUBEQA, hvis</h2>
<p>du er allergisk over for darolutamid eller et af de øvrige indholdsstoffer i NUBEQA (angivet i 
punkt 6).
-
du er en kvinde, som er eller kan blive gravid.
Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du tager NUBEQA, hvis 
- du har nyreproblemer 
- du har leverproblemer 
- du har en hjertesygdom, herunder problemer med hjerterytmen, eller hvis du tager lægemidler 
mod sådanne sygdomme 
- du har fået en operation for at behandle blodkarsygdomme. </p>
<p>Dette lægemiddel kan påvirke dine leverprøver. Hvis dine blodprøver viser unormale resultater for din 
leverfunktion, kan din læge beslutte at stoppe behandlingen permanent. </p>
<p>Børn og unge 
Dette lægemiddel må ikke anvendes til børn og unge under 18 år. Prostatakræft forekommer ikke hos 
denne aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med NUBEQA 
Fortæl altid lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget andre 
lægemidler eller planlægger at tage andre lægemidler. </p>
<p>De følgende lægemidler kan påvirke NUBEQAs virkning, eller NUBEQA kan påvirke disse 
lægemidler virkning ved behandling af:</p>
<ul>
<li>bakterieinfektioner, såsom rifampicin </li>
<li>epilepsi, såsom carbamazepin, phenobarbital, phenytoin </li>
<li>symptomer på let nedtrykthed og mild angst: prikbladet perikon (et naturlægemiddel) </li>
<li>højt kolesterol, såsom rosuvastatin, fluvastatin, atorvastatin, pitavastatin </li>
<li>svær ledbetændelse, svære tilfælde af hudsygdommen psoriasis og kræftformer: methotrexat </li>
<li>inflammatoriske tarmsygdomme: sulfasalazin </li>
</ul>
<p>Lægen kan derfor ændre dosis af de lægemidler, som du tager. </p>
<p>Graviditet, amning og frugtbarhed 
NUBEQA er ikke til kvinder. 
Dette lægemiddel kan muligvis påvirke frugtbarheden hos mænd. 
Følg disse råd under behandlingen og i op til 4 uger efter behandlingen er slut. 
- Anvend en meget sikker præventionsmetode for at undgå graviditet, hvis du dyrker sex med en 
kvinde, der kan blive gravid. 
- Brug et kondom for at beskytte det ufødte barn, hvis du dyrker sex med en gravid kvinde. </p>
<p>Trafik- og arbejdssikkerhed 
Det er ikke sandsynligt, at dette lægemiddel vil påvirke din evne til at føre motorkøretøj og betjene 
maskiner. </p>
<p>NUBEQA indeholder lactose 
Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nubeqa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nubeqa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er 
2 tabletter 2 gange dagligt </p>
<p>Lægen kan nedsætte din dosis til 1 tablet 2 gange dagligt, hvis du har lever- eller nyreproblemer. </p>
<p>Anvendelsesmåde 
Slug tabletterne hele, tag dem sammen med mad og et glas vand. </p>
<p>Lægen kan også ordinere andre lægemidler, mens du tager NUBEQA. </p>
<p>Hvis du har taget for meget NUBEQA 
Fortsæt behandlingen med den næste planlagte dosis. </p>
<p>Hvis du har glemt at tage NUBEQA 
Tag din glemte dosis så snart du husker det, før den næste planlagte dosis. Du må ikke tage en 
dobbeltdosis som erstatning for 1 eller flere glemte tabletter. </p>
<p>Hvis du holder op med at tage NUBEQA 
Du må ikke holde op med at tage dette lægemiddel, medmindre lægen fortæller dig det. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Bivirkninger ved NUBEQA forekommer med de følgende hyppigheder: </p>
<p>Hos patienter med ikke-metastatisk kastrationsresistent prostatakræft 
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer):</p>
<ul>
<li>træthed </li>
<li>blodprøver viser et nedsat antal af hvide blodlegemer af typen, der kaldes for neutrofiler </li>
<li>blodprøver viser forhøjede niveauer af stoffer, der dannes af leveren: bilirubin, 
aspartattransaminase </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer):</p>
<ul>
<li>forkalkning af hjertets kranspulsårer </li>
<li>hjertesvigt </li>
<li>udslæt </li>
<li>smerter i arme og ben </li>
<li>smerter i muskler og knogler </li>
<li>knoglebrud </li>
</ul>
<p>Hos patienter med metastatisk hormonfølsom prostatakræft 
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer):</p>
<ul>
<li>forhøjet blodtryk </li>
<li>udslæt </li>
<li>blodprøver viser et nedsat antal hvide blodlegemer af typen, der kaldes for neutrofiler </li>
<li>blodprøver viser forhøjede niveauer af stoffer, der dannes af leveren: bilirubin, 
alanintransaminase og aspartattransaminase </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer):</p>
<ul>
<li>knoglebrud </li>
<li>brystforstørrelse hos mænd </li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nubeqa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nubeqa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og hver blister efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>NUBEQA indeholder: 
Aktivt stof: darolutamid. Hver filmovertrukket tablet indeholder 300 mg darolutamid. 
Øvrige indholdsstoffer:</p>
<ul>
<li>calciumhydrogenphosphat (E 341) </li>
<li>croscarmellosenatrium </li>
<li>hypromellose </li>
<li>lactosemonohydrat </li>
<li>macrogol (E 1521) </li>
<li>magnesiumstearat (E 470b) </li>
<li>povidon (E 1201) </li>
<li>titandioxid (E 171) </li>
</ul>
<p>Se “NUBEQA indeholder lactose  "i punkt 2 for flere oplysninger. </p>
<p>Udseende og pakningsstørrelser 
De filmovertrukne tabletter (tabletter) er hvide til råhvide, ovale tabletter med en længde på 16 mm og 
en bredde på 8 mm. De er præget med "300 "på den ene side, og med "BAYER "på den anden side. </p>
<p>Hver æske indeholder:</p>
<ul>
<li>96 filmovertrukne tabletter i 6 blistre eller </li>
<li>112 filmovertrukne tabletter i 7 blistre </li>
</ul>
<p>Hver blistre indeholder 16 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Bayer AG 
51368 Leverkusen 
Tyskland </p>
<p>Fremstiller 
Orion Corporation, Orion Pharma 
24100 Salo 
Finland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Bayer SA-NV 
Tél/Tel: +32-(0)2-5356Lietuva 
UAB Bayer 
Tel. +37 05 23 36 България 
Байер България ЕООД 
Tел.: +359 (0)2 424 72 Luxembourg/Luxemburg 
Bayer SA-NV 
Tél/Tel: +32-(0)2-535 63 Česká republika 
Bayer s.r.o. 
Tel: +420 266 101 Magyarország 
Bayer Hungária KFT 
Tel:+36 14 87-41 Danmark 
Bayer A/S 
Tlf.: +45 45 23 50 Malta 
Alfred Gera and Sons Ltd. 
Tel: +35 621 44 62 Deutschland 
Bayer Vital GmbH 
Tel: +49 (0)214-30 513 Nederland 
Bayer B.V. 
Tel: +31-23-799-1Eesti 
Bayer OÜ 
Tel: +372 655 8Norge 
Bayer AS 
Tlf: +47 24 11 18 Ελλάδα 
Bayer Ελλάς ΑΒΕΕ 
Τηλ: +30 210-618 75 Österreich 
Bayer Austria Ges.m.b.H. 
Tel: +43-(0)1-711 46-0 
España 
Bayer Hispania S.L. 
Tel: +34-93-495 65 Polska 
Bayer Sp. z.o.o. 
Tel: +48 22 572 35 France 
Bayer HealthCare 
Tél (N° vert): +33-(0)800 87 54 Portugal 
Bayer Portugal, Lda. 
Tel: +351 21 416 42 Hrvatska 
Bayer d.o.o. 
Tel: +385-(0)1-6599 România 
SC Bayer s.r.l. 
Tel: +40 21 529 59 Ireland 
Bayer Limited 
Tel: +353 1 216 3Slovenija 
Bayer d. o. o. 
Tel: +386 1 58 14 Ísland 
Icepharma hf. 
Sími: +354 540 8Slovenská republika 
Bayer spol. s r.o. 
Tel. +421 2 59 21 31 Italia 
Bayer S.p.A. 
Tel: +39 02 397 Suomi/Finland 
Bayer Oy 
Puh/Tel: +358 20 785 Κύπρος 
NOVAGEM Limited 
Tηλ: +357 22 48 38 Sverige 
Bayer AB 
Tel: +46 (0) 8 580 223 Latvija 
SIA Bayer 
Tel: +371 67 84 55 United Kingdom (Northern Ireland) 
Bayer AG 
Tel: +44-(0)118 206 3 </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>
<p>BILAG IV </p>
<p>VIDENSKABELIGE KONKLUSIONER OG BEGRUNDELSE FOR ÆNDRING AF 
BETINGELSERNE 
FOR MARKEDSFØRINGSTILLADELSEN </p>
<p>Videnskabelige konklusioner </p>
<p>Under hensyntagen til PRAC's vurderingsrapport om PSUR'en/PSUR'erne for darolutamid er PRAC 
nået frem til følgende videnskabelige konklusioner: </p>
<p>I lyset af tilgængelige data om hepatotoksicitet og leverfunktionsprøver fra kliniske studier og 
spontane indberetninger mener PRAC, at den nuværende advarsel om hepatotoksicitet og beskrivelse 
af leverfunktionsprøver bør styrkes. PRAC har konkluderet, at produktinformationen for produkter, 
der indeholder darolutamid, skal ændres i henhold hertil. </p>
<p>CHMP har gennemgået PRAC's anbefaling og er enig i de overordnede konklusioner og begrundelser 
for anbefalingen. </p>
<p>Begrundelser for ændring af betingelserne for markedsføringstilladelsen/-tilladelserne </p>
<p>På baggrund af de videnskabelige konklusioner for darolutamid  er CHMP af den opfattelse, at 
benefit/risk-forholdet for lægemidlet/lægemidlerne indeholdende darolutamid forbliver uændret under 
forudsætning af, at de foreslåede ændringer indføres i produktinformationen. </p>
<p>CHMP anbefaler, at betingelserne for markedsføringstilladelsen/-tilladelserne ændres. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-1cafc851e1f0aed5863b6a73ba46d0f7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nubeqa Package Leaflet for language en"
Description: "ePI document Bundle for nubeqa Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-1cafc851e1f0aed5863b6a73ba46d0f7"
* entry[0].resource = composition-en-1cafc851e1f0aed5863b6a73ba46d0f7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp1cafc851e1f0aed5863b6a73ba46d0f7"
* entry[=].resource = mp1cafc851e1f0aed5863b6a73ba46d0f7
                            
                    
Instance: bundlepackageleaflet-da-1cafc851e1f0aed5863b6a73ba46d0f7
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for nubeqa Package Leaflet for language da"
Description: "ePI document Bundle for nubeqa Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-1cafc851e1f0aed5863b6a73ba46d0f7"
* entry[0].resource = composition-da-1cafc851e1f0aed5863b6a73ba46d0f7

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp1cafc851e1f0aed5863b6a73ba46d0f7"
* entry[=].resource = mp1cafc851e1f0aed5863b6a73ba46d0f7
                            
                    



Instance: mp1cafc851e1f0aed5863b6a73ba46d0f7
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product NUBEQA 300 mg film-coated tablets"
Description: "NUBEQA 300 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/20/1432/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "NUBEQA 300 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 1cafc851e1f0aed5863b6a73ba46d0f7ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "nubeqa"

* status = #current
* mode = #working

* title = "List of all ePIs associated with nubeqa"

* subject = Reference(mp1cafc851e1f0aed5863b6a73ba46d0f7)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#nubeqa "nubeqa"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-1cafc851e1f0aed5863b6a73ba46d0f7) // nubeqa en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-1cafc851e1f0aed5863b6a73ba46d0f7) // nubeqa da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-1cafc851e1f0aed5863b6a73ba46d0f7
InstanceOf: List

* insert 1cafc851e1f0aed5863b6a73ba46d0f7ListRuleset
    